- Home
- CARS vs GYRE Comparison
CARS vs GYRE Comparison
Compare CARS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- GYRE
- Stock Information
- Founded
- CARS 1998
- GYRE 2002
- Country
- CARS United States
- GYRE United States
- Employees
- CARS N/A
- GYRE N/A
- Industry
- CARS Motor Vehicles
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- GYRE Health Care
- Exchange
- CARS Nasdaq
- GYRE Nasdaq
- Market Cap
- CARS 1.1B
- GYRE 1.1B
- IPO Year
- CARS 2017
- GYRE N/A
- Fundamental
- Price
- CARS $17.63
- GYRE $10.95
- Analyst Decision
- CARS Buy
- GYRE
- Analyst Count
- CARS 4
- GYRE 0
- Target Price
- CARS $23.00
- GYRE N/A
- AVG Volume (30 Days)
- CARS 481.4K
- GYRE 129.2K
- Earning Date
- CARS 02-20-2025
- GYRE 11-13-2024
- Dividend Yield
- CARS N/A
- GYRE N/A
- EPS Growth
- CARS N/A
- GYRE N/A
- EPS
- CARS 0.59
- GYRE N/A
- Revenue
- CARS $718,327,000.00
- GYRE $105,033,000.00
- Revenue This Year
- CARS $6.94
- GYRE $25.32
- Revenue Next Year
- CARS $4.86
- GYRE $12.95
- P/E Ratio
- CARS $29.88
- GYRE N/A
- Revenue Growth
- CARS 5.98
- GYRE N/A
- 52 Week Low
- CARS $15.05
- GYRE $8.26
- 52 Week High
- CARS $21.24
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- CARS 50.51
- GYRE 48.93
- Support Level
- CARS $16.19
- GYRE $9.51
- Resistance Level
- CARS $17.80
- GYRE $11.11
- Average True Range (ATR)
- CARS 0.47
- GYRE 0.85
- MACD
- CARS 0.09
- GYRE 0.04
- Stochastic Oscillator
- CARS 85.76
- GYRE 29.33
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.